Views & Analysis | Perspectives on pharma industry issues

Digital

Changing Faces: Digital and supplier hires, June and July 20...

The pharma-adjacent tech and services sectors continued to attract experienced leadership talent during June and July.

Patients

Innovation can transform NHS care, but scaling is the missin...

Innovation is already improving care across the NHS, but we are not yet consistently delivering at scale for the benefit of patients

R&D

A physiotherapist assists an ALS patient

Treating mechanisms, not symptoms: ALS R&D today

The ALS clinical trial landscape is characterised by a significant number of active trials and sponsors, including MediciNova's Ph3 with MN-166.

R&D

Why storage resilience will protect the future of CAR-T

Cell and gene therapies are changing the way pharmaceutical organisations think about sample storage.

Patients

Reshaping the future of patient-centric drug development

Strategic partnerships, robust quality systems, and manufacturing know-how will support next-generation therapies with patient-centric designs.

Views & Analysis

Has pharma been too slow to respond to coronavirus?

The new coronavirus strain emerging in China is making headlines across the world, with the disease sending entire cities into lockdown in a bid to control its spread.

White Papers

5-big-challenges-for-pharmaceutical-marketers-1200x675

5 big challenges for pharmaceutical marketers (and their age...

For the patient demanding access to the latest medicine or the healthcare professional desperate to be able to use a new advance in treatment, every extra day, week or month waiting counts.

Views & Analysis

"Fake news" and credibility in medical publishing

Natalie Yeadon looks at how the industry can help healthcare professionals, patients, and their families combat false and misleading scientific information.

Sales & Marketing

Personalisation is the biggest lie brands keep telling

Pharma brands need to move beyond surface-level personalisation and focus on measurable impact.

Sales & Marketing

M&A trends in diagnostics and life sciences tools

The diagnostics and life sciences tools sector is attracting continued investor interest across both private equity and large corporates.

Digital

Changing Faces: Digital and supplier hires, June and July 20...

The pharma-adjacent tech and services sectors continued to attract experienced leadership talent during June and July.

Digital

Australia, AI, and Autolomous

pharmaphorum spoke with Alexander Seyf, CEO of Autolomous, about the future of AI in Australian biotech.

Market Access

Europe’s new HTA reality: The JCA, one year on

Here, we examine the early realities of JCA implementation, exploring whether the system is delivering greater alignment across European markets.

Market Access

Three separate injections - blue, red, and yellow - take off against black background

Why global pharmaceutical reforms are quietly redirecting ra...

Publication of the 2026 Pharma Package by the Council of the EU represents the most significant reform of EU pharmaceutical legislation in over 20 yrs